BrainScope Expands Board and Launches Advanced Deep Learning Platform to Enhance Brain Health Insights
BETHESDA, Md., June 11, 2025--(BUSINESS WIRE)--BrainScope®, a leader in AI-enabled EEG technology for brain health assessment, today announced the launch of its next-generation deep learning platform. BrainScope developed and has commercialized the first FDA-cleared AI/machine learning medical device in the field of neurology. Building on that foundation in machine learning, BrainScope's new capabilities enhance its ability to deliver fast, objective, and clinically actionable insights across brain health conditions including concussion, stroke, and early Alzheimer's detection.
The integration of deep learning into BrainScope's proprietary platform marks a major leap forward in automated EEG analysis. BrainScope's new Large Neural Model platform brings many of the breakthroughs of Large Language Models (LLMs) to bear on EEG data, eliminating the need for specialized qEEG interpretation. This novel and proprietary approach enhances BrainScope's first-in-class machine learning foundation, with the potential to significantly expand its utility across clinical care, research, and biopharma by enabling the development of more refined biomarkers to support precision-driven clinical trial recruitment, early diagnosis, personalized treatment, and improved patient outcomes.
To help guide the company as it expands its clinical program and commercial activities, BrainScope has announced key updates to its Board of Directors. Ralph Terkowitz, who has served on BrainScope's Board since 2023, has been elected Chairman. A former General Partner at ABS Capital Partners, Terkowitz brings decades of experience helping technology companies grow and scale. He also serves on the Board of The 10,000 Brains Project and is Co-Chairman of The Robert Packard Center for ALS Research at Johns Hopkins. In his expanded role, Terkowitz will guide BrainScope's continued growth and adoption of its AI-powered brain health platform.
Also joining the Board are Mike Genau, a seasoned global MedTech executive and former President of Medtronic's Americas Region, and Brian Shea, who oversees healthcare investments and deal origination as Head of Origination at Aon Advantage Funds. Genau led a $7B business unit at Medtronic and brings deep expertise in scaling medical technologies and guiding commercial strategy. Shea offers a valuable perspective at the intersection of finance, healthcare, and technology.
"We're thrilled to elevate Ralph to the Chairman role and honored to welcome Mike and Brian to our Board during this pivotal moment in BrainScope's evolution," said Laurie Silver, CEO of BrainScope. "Ralph has been an invaluable advisor as we've developed and launched our next-generation EEG-based Large Neural Model platform. Mike's leadership in MedTech and Brian's strategic investment insight will be beneficial as we scale commercially, drive clinical innovation in expanded markets, and bring in new investment partners. To reflect our expanded capabilities, we've also launched a new website showcasing our deep learning technology and broader brain health mission."
"It's exciting to take on the role of Chairman at such a transformative time," said Ralph Terkowitz. "BrainScope is turning groundbreaking science into meaningful real-world impact, and has demonstrated success in using qEEG coupled with computational neuroscience as a diagnostic tool to aid in assessment of many neurological conditions including stroke, concussions, and early Alzheimer's. I look forward to helping the team expand this potentially groundbreaking opportunity."
About BrainScope
BrainScope is a leading neurotechnology company with over 15 years of experience advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope's initial commercial product remains the only point-of-care technology that objectively assesses head-injured patients for both brain bleeds and concussions. The company is now advancing novel biomarkers for early Alzheimer's detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and brain fog. For more information, please visit brainscope.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611423351/en/
Contacts
Media Contact: Kissy BlackLotos Nile615-310-1894info@brainscope.com
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Augnition Labs Announces FDA Classification for Flagship Product, AugMem(TM)
NEW YORK CITY, NEW YORK / ACCESS Newswire / June 12, 2025 / Augnition Labs, a neurotechnology company developing science-driven tools to advance cognitive health, today announced that its flagship product, AugMem™, has been classified by the FDA as a Prescription Use Cognitive Assessment Aid (PTY). This significant milestone paves the way for clinical deployment to support evaluation of cognitive function and help identify changes that may indicate early cognitive decline. Grounded in more than two decades of neuroscientific research by Co-Founder and Chief Scientific Advisor, Dr. Michael Yassa, AugMem™ evaluates pattern separation - a core brain process that enables us to form distinct memories. Subtle impairments in this mechanism often precede clinical symptoms of cognitive decline by 10-15 years. "Early detection is critical. If we wait until memory loss is obvious, decline can be irreversible," said Yassa. "This FDA classification is a major step forward. It opens the door for us to deploy it in healthcare settings. Our goal is to make ultrasensitive cognitive assessment available where it's needed most-at the frontlines of care, before symptoms become disabling." In addition to this regulatory milestone, Augnition Labs also announced key leadership appointments to strengthen its path to growth and impact. Ernst Wodrada, a seasoned executive in the medical technology industry, has joined Augnition as President. Ernst brings leadership experience from global healthcare organizations, including Philips, where he led efforts in imaging, image-guided therapy, and healthcare innovation. "I am honored and excited to join Augnition Labs, working alongside this fantastic team to forge meaningful partnerships with clinical experts and investors," Wodrada said. "Cognitive decline presents profound challenges, and together, we are committed to pioneering solutions that empower individuals and caregivers." Ali Kennedy Scott, a member of Augnition's founding team, will step into the role of Managing Director. A former Bain & Company consultant, Kennedy Scott brings expertise in growth strategy, organizational effectiveness, and customer insight, with experience spanning healthcare, consumer products, and private equity-backed ventures. The company also welcomes Dr. Chris Bun as Head of Technology. With a background in AI, machine learning, and healthcare technology, Dr. Bun will lead development of Augnition's core platform, applying advanced AI and user-centered design to cognitive assessment tools. "We are deeply proud of the momentum behind AugMem™ and of this team that's come together to shape the future of cognitive assessments," said Kennedy Scott. "This FDA classification is a foundational step in our mission to equip patients, caregivers, and healthcare providers with tools that enhance clarity, agency, and hope." Augnition collaborates with leading academic institutions, industry researchers, clinicians, and healthcare systems to create accessible, evidence-based tools for cognitive health. About Augnition LabsAugnition Labs develops science-driven tools to advance cognitive health. The company was founded on the scientific work of Dr. Michael Yassa, a globally recognized expert in the neurobiology of memory and Alzheimer's Disease. With a focus on clinical utility, human-centered design, and early intervention, Augnition empowers patients, researchers, and clinicians to better understand the brain and respond to change. SOURCE: Augnition Labs press release
Yahoo
an hour ago
- Yahoo
Dr. Pepper zero recall upgraded in Georgia, South Carolina
SAVANNAH, Ga. (WSAV) — Dr. Pepper is recalling over 19,000 cases of their Zero Sugar soda in three Southern states. The recalled sodas, which are labeled as having zero sugar, actually contained the full sugar product. Because the cans were mislabeled as having zero sugar, they could cause a health risk for diabetics or others who need to limit their sugar intake or avoid it altogether. The voluntary recall was initiated for Zero Sugar Dr. Peppers with a best by date of Feb. 16, 2026, in Georgia, Florida and South Carolina. The sodas were sold in 12-pack and 24-pack cases of 12-ounce cans. The affected product code is XXXXRS05165. The FDA upgraded the recall to Class II last week due to the health risks associated. If you purchased Dr Pepper drinks matching these descriptions, you can return them to the place you purchased them for a full refund or safely dispose of them. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Newsweek
an hour ago
- Newsweek
Dried Fruit Recall Map Shows 19 States With New Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Turkana Food Inc. has issued a recall for their dried apricots because the package label does not disclose that the product contains sulfites. Newsweek reached out to the company via phone Thursday and left a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. What To Know According to the FDA alert, the Floria brand dried apricots have an expiration date of November 2026. The impacted product has a LOT number of 440090478-15-333 that can be found at the bottom of the packaging. The product has a UPC Label of 2539560010 that can be seen on a sticker at the top of the package, the FDA says. The dried apricots were distributed in Florida, Kentucky, Virginia, New York, New Jersey, Tennessee, Massachusetts, Texas, Illinois, Indiana, Michigan, Rhode Island, Pennsylvania, North Carolina, Maryland, Ohio, Alabama, Missouri and California. There have been no reported illnesses as of Thursday, the FDA says. The alert also has pictures of the recalled product that potential customers can cross reference. Below is a map of the impacted states: What People Are Saying The FDA alert in part: "The recall was the result of a routine sampling performed by the New York State Department of Agriculture and markets which revealed that the finished products contained Sulfites that were not listed on the product labelling. The company has ceased production and distribution of the products as FDA and the company continue their investigation to correct the issue with the manufacturer." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued. It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled dried apricots are asked not to eat them and return them to the original place of purchase for a refund, the FDA says. People with additional questions may call Turkana Foods Inc. at 908-810-8800 on weekdays from 8 a.m. to 6 p.m. ET.
